News

A fingerprint of exhaled breath
Enlarge image

ResearchSwitzerland

A fingerprint of exhaled breath

04.04.2013 - Researchers from ETH Zurich have shown that the individual fingerprint of exhaled breath can be used for diagnostic purposes.

The team headed by Renato Zenobi reports in the journal PLoS that real-time analysis of the metabolic pattern found in exhaled breath can help to diagnose and monitor diseases. Using mass spectrometry (SESI-MS), the ETH researchers found that the chemical "fingerprint" of exhaled breath of 11 volunteers showed an individual core pattern and remained stable over time. According to the researchers, linking up that metabolic ID with genetic susceptibility to diseases can help diagnosing manifestation of diseases more individually. Shortly before, US researchers had published results of a MS-based study for diagnosis of heart failure

"We did find some small variations during the day, but overall the individual pattern stays sufficiently constant to be useful for medical purposes," says Pablo Martinez-Lozano Sinues, senior scientist in Zenobi's research group. To carry out these measurements, Zenobi and his colleagues modified commercial mass spectrometers by adding a breath sampling inlet line that delivers exhaled breath from a mouth piece directly into the ion source of the instrument. Mass spectra showing peaks of roughly 100 compounds in breath can be easily and rapidly obtained. 

The researchers are working to recognise characteristic patterns of lung diseases with the same technology. Although the potential usefulness of analysing breath for medical diagnosis has been known, it is rarely done in academic medicine. "This might be due to the fact that existing methods for breath analysis are either rather slow, or are limited to a small number of compounds that they can detect," says Sinues. Compared to analysis of blood or urine, a significant advantage of the ETH researchers’ approach is that the breath fingerprint is available within seconds. Another benefit is that exhaling into the ion source of a mass spectrometer is completely non-invasive. They researchers see huge potential to use the method as a tool for early detection of certain diseases in risk populations and in therapy monitoring.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/a-fingerprint-of-exhaled-breath.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014